Zimmer Biomet Q4 EPS $2.42 Tops Estimate on Strong Hip, Knee Demand
Zimmer Biomet delivered Q4 EPS of $2.42, surpassing the $2.38 consensus by $0.04 and outpacing last year’s $2.31 per share. The beat was fueled by strong demand for hip and knee devices, boosting implant revenues.
1. Q4 Earnings Beat Estimates
Zimmer Biomet reported fourth-quarter earnings per share of $2.42, exceeding the $2.38 consensus and up from $2.31 in Q4 2024. Revenue also topped forecasts, reflecting broad-based growth across its orthopedic business.
2. Hip and Knee Device Demand Drives Growth
Robust uptake of hip and knee implants drove the quarter’s performance, with healthy volumes in both mature and emerging markets. Management cited aging demographics and a rebound in elective procedures as key factors sustaining device demand.
Related News
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
MMYT
MakeMyTrip Q4 Cash Hits $782M with 1.82% Margin and 15.2% Accommodation Growth
MMYT•
JPM
J.P. Morgan Joins SpaceX $1.75 Trillion Nasdaq IPO With $1.45B Bitcoin Disclosure
JPM•
SONM
DNA X nets $6.3 million in Q1 from $15 million asset sale, repays debt
SONM•
Sources
ZF